Full-Time

Magnetic Resonance Sales Leader

North America

Posted on 10/5/2025

Philips

Philips

Manufactures sleep therapy and respiratory devices

Compensation Overview

$325k - $400k/yr

+ Target Incentive + Base Salary Component + Fleet/Car

No H1B Sponsorship

United States

In Person

Field role; travel to customer sites; not remote; office-based 3 days requirement not applicable.

Category
Sales & Account Management (2)
,
Requirements
  • Strong business and financial acumen, excellent negotiation skills, strong communication and presentation skills, and outstanding people management/development skills
  • Proven experience in sales leadership, with a strong track record of coaching and developing other leaders to achieve high performance and drive business growth
  • Solid understanding of the Diagnostic Imaging market in North America
  • 11+ years of experience in areas such as Sales, Marketing, Business Development, E-commerce, Marketing technology, Healthcare or equivalent
  • Proven experience in strategic account management or corporate sales leadership within the medical device or healthcare industry
  • Strong understanding of imaging modalities, clinical workflows, and healthcare economics
  • Demonstrated ability to lead multidisciplinary teams and manage complex sales cycles
  • Excellent communication, negotiation, and relationship-building skills
  • Bachelor’s degree required; advanced degree preferred
  • You must be able to successfully perform the following minimum Physical, Cognitive and Environmental job requirements with or without accommodation for this Sales position.
  • US work authorization is a precondition of employment.
Responsibilities
  • Champion the MR Global Business Unit across North America by shaping regional strategy, aligning cross-functional priorities, and advocating for market-specific needs. Act as the primary conduit between North American stakeholders and global leadership—ensuring that regional insights, challenges, and growth opportunities are clearly represented in global forums and decision-making processes.
  • Drive market share growth and business performance by leading Sales Specialists and Marketing, while collaborating closely with Imaging Account Managers, Clinical Education and Service teams.
  • Partner with the National Sales Zone Leaders and NAM Account Executive teams to accelerate MR business expansion and profitability across Philips.
  • Reviews and operationalizes the sales strategy and plan, including sales forecasts and Annual Operating Plan (AOP) execution, to drive revenue growth, optimize market opportunities, and consistently achieve sales targets.
  • Build strong relationships with key clients and stakeholders by actively engaging in regular communication at executive and operational levels.
  • Drives continuous improvement by applying LEAN principles to enhance Market to Order processes and spearheads customer satisfaction initiatives to boost client retention and loyalty.
  • Leads succession planning and comprehensive talent management, driving employee selection, performance management, compensation management, and career development in alignment with organizational operational goals.
  • Drive budget planning and P&L management to optimize profitability and enhance financial performance.
  • Cross-Functional Collaboration - coordinate with marketing, finance, operations, and clinical teams to ensure seamless execution.
Desired Qualifications
  • Advanced degree preferred

Philips Respironics designs sleep and respiratory care devices, including CPAP and BiPAP machines, ventilators, and oxygen concentrators, plus related systems. These devices deliver regulated air pressure, support or assist breathing, and provide concentrated oxygen, often paired with software and data tools for monitoring. The division differentiates itself through its long history within Philips and its integrated ecosystem that connects devices with analytics and clinical support across hospital, clinic, and home settings. Its goal is to improve quality of life and clinical outcomes for people with sleep and respiratory conditions by offering reliable devices, patient support, and data-driven care.

Company Size

N/A

Company Stage

Acquired

Total Funding

$5.1B

Headquarters

Murrysville, Pennsylvania

Founded

1891

Simplify Jobs

Simplify's Take

What believers are saying

  • BioTelemetry acquisition in 2020 expands remote heart monitoring.
  • $479 million settlement in September 2023 closes US litigation.
  • New silicone foam validated safe, enabling global device sales.

What critics are saying

  • ResMed seizes US sleep market share within 6-12 months.
  • FDA consent decree blocks US sales until after 2026.
  • January 2024 US ventilation exit halves revenue permanently.

What makes Philips unique

  • Pioneered CPAP therapy as standard for sleep apnea since 1976.
  • Leads in non-invasive ventilation and home respiratory support.
  • Integrates devices with software for data-driven clinical outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

401(k) Retirement Plan

401(k) Company Match

Unlimited Paid Time Off

Health Savings Account/Flexible Spending Account

Company News

HIT Consultant
Apr 12th, 2024
Philips Respironics Reaches Final Agreement With Us Regulators On Sleep Apnea Device Recall

<img src="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp" alt="Philips Respironics Reaches Final Agreement with US Regulators on Sleep Apnea Device Recall. " class="wp-image-78777" srcset="https://hitconsultant.net/wp-content/uploads/2024/04/Philips.webp 700w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-300x161.webp 300w, https://hitconsultant.net/wp-content/uploads/2024/04/Philips-290x155.webp 290w" sizes="(max-width: 700px) 100vw, 700px">What You Should Know: – Philips Respironics, a subsidiary of Royal Philips, has finalized a consent decree with the US Department of Justice (DOJ) and Food and Drug Administration (FDA) to address issues raised during a 2021 inspection of a Philips facility in Pennsylvania.– The agreement focuses on Philips Respironics’ operations in the US, particularly regarding the recall of certain sleep and respiratory care devices.– The company’s focus will now be on completing remediation efforts, ensuring patient safety, and regaining regulatory approval to resume sales of new devices in the US.Focus on Remediation and ComplianceThe consent decree outlines a roadmap for Philips Respironics to:Prioritize Recall Remediation: Philips will continue efforts to remediate millions of sleep apnea and respiratory care devices recalled in June 2021 due to potential health risks associated with degraded sound abatement foam.Independent Oversight: Independent experts will be brought in to review recall remediation efforts and ensure Philips Respironics’ business operations comply with FDA regulations.Continued Patient Support: Philips Respironics can continue servicing existing devices in the hands of patients and healthcare providers. Additionally, they can sell accessories, consumables, and replacement parts for these devices.Sales Restrictions Remain in USThe FDA has not yet authorized Philips Respironics to resume sales of new CPAP, BiPAP, or other respiratory care devices in the US. This restriction will remain in place until Philips meets the requirements outlined in the consent decree.Global Sales Continue with RestrictionsPhilips Respironics can continue to sell new devices, accessories, consumables, and replacement parts outside the US,  subject to specific requirements.Safety of Devices with New Foam ConfirmedPhilips Respironics has conducted tests on devices using a new silicone sound abatement foam and found no safety issues. Patients can continue to use these devices following the instructions for use.Financial ImpactPhilips anticipates incurring costs associated with remediation activities and profit disgorgement related to US sales. These costs are estimated at 100 basis points in 2024.  The company’s previously announced 2023-2025 financial outlook remains unchanged,  already factoring in the consent decree. “Strengthening patient safety and quality remains Philips’ highest priority and the increased scrutiny will help us to improve even more

Goodrich Pharmacy
Jan 29th, 2024
Phillips Suspends U.S. Sales of CPAP, Ventilator Machines After Recall

Following a recall of millions of its breathing machines that began in mid-2021, Phillips Respironics announced Monday that it would halt sales of all such machines within the United States.

Parker Waichman LLP
Mar 23rd, 2023
Sleep Apnea Patients Suffer While Waiting To Receive Their Repaired Philips CPAP Machines

In June of 2021, Philips began a recall of over five million of its breathing devices due to toxic fume and substances emanating from the devices’ sound abatement foam.

Digital Journal
Jan 13th, 2023
Ultrasound Market Share | Market | Report | Analysis 2032 | Key Players: Fujifilm Holdings Corporation, Analogic Corporation, Siemens Healthcare among others

February 2019 – Koninklijke Philips launched the EPIQ Elite ultrasound system in the market.

VentureBeat
Oct 26th, 2022
Philips Norelco Brings Movember To Roblox With Shavetopia

Register now for your free virtual pass to the Low-Code/No-Code Summit this November 9. Hear from executives from Service Now, Credit Karma, Stitch Fix, Appian, and more. Learn more. Philips Norelco is creating an interactive metaverse experience called Shavetopia in Roblox, based around the Movember trend. For anyone who doesn’t know what that is, Movember is where people grow facial hair for the entire month of November. The portmanteau comes from adding the word mustache to the name of the month

INACTIVE